Skip to main content
Top
Published in: Journal of Anesthesia 5/2014

01-10-2014 | Original Article

Interaction between rosuvastatin and rocuronium in rat sciatic-gastrocnemius nerve-muscle preparation

Authors: Ashwin K. Panchasara, Jayshree C. Patel, Vishalkumar K. Vadgama, Manish J. Barvaliya, C. B. Tripathi

Published in: Journal of Anesthesia | Issue 5/2014

Login to get access

Abstract

Purpose

Long-term use of rosuvastatin may be associated with myotoxicity. Statins are one of the groups commonly found to be associated with neuromuscular weakness. The present study was designed to investigate the interaction between rosuvastatin and rocuronium in vivo by using a sciatic-gastrocnemius nerve-muscle preparation of rat.

Methods

In our study groups, animals received rosuvastatin 2 mg/kg for 14 and 28 days. Train of four (TOF) stimulation was applied to the sciatic nerve, and gastrocnemius muscle contractions were recorded in Wistar albino rats. Intravenous infusion of rocuronium was given until the twitch responses were abolished. We ultimately compared the effective dose required for a desired effect in 95% of the population (ED95), duration 25 %, deep block, recovery index, and time for returning of TOF ratio to 0.9 between the active control and study groups.

Results

Chronic administration of rosuvastatin at a dose of 2 mg/kg for 28 days significantly reduced the ED95 of rocuronium as compared to the active control group. Deep block and duration 25 % were increased by 3.5 and 2.5 times, respectively, compared to the active control group. The spontaneous recovery of neuromuscular block was delayed, as evidenced by the prolonged recovery index and increase in time required for a return of the TOF ratio to 0.9.

Conclusion

The neuromuscular blocking potency of rocuronium is increased and recovery is delayed in rats that pre-treated with rosuvastatin.
Literature
1.
go back to reference Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Bernard R, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.PubMedCrossRef Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Bernard R, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.PubMedCrossRef
2.
go back to reference Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60.PubMedCrossRef Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60.PubMedCrossRef
3.
4.
go back to reference Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001;175(9):486–9.PubMed Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001;175(9):486–9.PubMed
5.
go back to reference Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-Co A reductase inhibitors (statins): a critical overview. Adv Ther. 1998;15:218–28. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-Co A reductase inhibitors (statins): a critical overview. Adv Ther. 1998;15:218–28.
6.
go back to reference Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 1994;17:891–4.PubMedCrossRef Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 1994;17:891–4.PubMedCrossRef
7.
go back to reference Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolaemic patients. Metabolism. 1994;43:59–64.CrossRef Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolaemic patients. Metabolism. 1994;43:59–64.CrossRef
8.
go back to reference Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.PubMedCrossRef Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.PubMedCrossRef
10.
12.
go back to reference Savarese JJ, Caldwell JE, Lien CA, Miller RD. Pharmacology of muscle relaxants and their antagonist. In: Miller Ronald D, editor. Miller’s Anesthesia. Philadelphia: Elsevier Churchill Livingstone; 2000. p. 412–90. Savarese JJ, Caldwell JE, Lien CA, Miller RD. Pharmacology of muscle relaxants and their antagonist. In: Miller Ronald D, editor. Miller’s Anesthesia. Philadelphia: Elsevier Churchill Livingstone; 2000. p. 412–90.
13.
go back to reference Maramattom BV, Wijdicks EF. Acute neuromuscular weakness in the intensive care unit. Crit Care Med. 2006;34:2835–41.PubMedCrossRef Maramattom BV, Wijdicks EF. Acute neuromuscular weakness in the intensive care unit. Crit Care Med. 2006;34:2835–41.PubMedCrossRef
14.
go back to reference Mishra Y, Ramzan I. Interaction between succinylcholine and ranitidine in rats. Can J Anesth. 1993;40:32–7.PubMedCrossRef Mishra Y, Ramzan I. Interaction between succinylcholine and ranitidine in rats. Can J Anesth. 1993;40:32–7.PubMedCrossRef
15.
go back to reference Fu C, Mishra Y, Ramzan I. Omeprazole potentiates atracurium and succinylcholine paralysis in vivo in rats. Anesth Analg. 1994;78(3):527–30.PubMedCrossRef Fu C, Mishra Y, Ramzan I. Omeprazole potentiates atracurium and succinylcholine paralysis in vivo in rats. Anesth Analg. 1994;78(3):527–30.PubMedCrossRef
16.
go back to reference Conor D, Jennifer M. Monitoring of neuromuscular block. Contin Educ Anaesth Crit Care Pain. 2006;6(1):7–12.CrossRef Conor D, Jennifer M. Monitoring of neuromuscular block. Contin Educ Anaesth Crit Care Pain. 2006;6(1):7–12.CrossRef
17.
go back to reference Viby-Mogensen Jorgen. Neuromuscular monitoring. In: Miller Ronald D, editor. Miller’s Anesthesia. Philadelphia: Elsevier Churchill Livingstone; 2000. p. 1351–66. Viby-Mogensen Jorgen. Neuromuscular monitoring. In: Miller Ronald D, editor. Miller’s Anesthesia. Philadelphia: Elsevier Churchill Livingstone; 2000. p. 1351–66.
18.
go back to reference Saitoh Y, Toyooka H, Amaha K. Recoveries of post-tetanic twitch and train-of-four responses after administration of vecuronium with different inhalation anaesthetics and neuroleptanaesthesia. Br J Anaesth. 1993;70:402–4.PubMedCrossRef Saitoh Y, Toyooka H, Amaha K. Recoveries of post-tetanic twitch and train-of-four responses after administration of vecuronium with different inhalation anaesthetics and neuroleptanaesthesia. Br J Anaesth. 1993;70:402–4.PubMedCrossRef
19.
go back to reference Ghosh MN. Toxicity studies. In: Ghosh SK, editor. Fundamentals of experimental pharmacology. Kolkata: Hilton & company; 2011. p. 165–72. Ghosh MN. Toxicity studies. In: Ghosh SK, editor. Fundamentals of experimental pharmacology. Kolkata: Hilton & company; 2011. p. 165–72.
20.
go back to reference Bersot TP. Drug therapy for Hypercholesterolemia and Dyslipidemia. In: Laurence LB, Parker KL, editors. Goodman and Gilman’s The Pharmacological Basics of Therapeutics. New York: The McGraw-Hill Companies, Inc; 2011. p. 877–908. Bersot TP. Drug therapy for Hypercholesterolemia and Dyslipidemia. In: Laurence LB, Parker KL, editors. Goodman and Gilman’s The Pharmacological Basics of Therapeutics. New York: The McGraw-Hill Companies, Inc; 2011. p. 877–908.
21.
go back to reference Sidaway J, Wang Y, Marsden AM, Orton TC, Westwood FR, Azuma CT, Scott RC. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica. 2009;39(1):90–8.PubMedCrossRef Sidaway J, Wang Y, Marsden AM, Orton TC, Westwood FR, Azuma CT, Scott RC. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica. 2009;39(1):90–8.PubMedCrossRef
22.
go back to reference McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(Suppl):28B–32B.PubMedCrossRef McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(Suppl):28B–32B.PubMedCrossRef
23.
go back to reference Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg. 1995;80(4):754–9.PubMed Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg. 1995;80(4):754–9.PubMed
24.
go back to reference Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, Nicchia GP, Svelto M, Chiesa G, Sirtori C, Scanziani E, Rizzo C, De Vito D, Conte Camerino D. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol. 2006;149(7):909–19.PubMedCrossRefPubMedCentral Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, Nicchia GP, Svelto M, Chiesa G, Sirtori C, Scanziani E, Rizzo C, De Vito D, Conte Camerino D. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol. 2006;149(7):909–19.PubMedCrossRefPubMedCentral
25.
go back to reference Brannigan G, Hénin J, Law R, Eckenhoff R, Klein ML. Embedded cholesterol in the nicotinic acetylcholine receptor. Proc. Nat. Acad. Sci. USA. 2008;105:14418–23.PubMedCrossRefPubMedCentral Brannigan G, Hénin J, Law R, Eckenhoff R, Klein ML. Embedded cholesterol in the nicotinic acetylcholine receptor. Proc. Nat. Acad. Sci. USA. 2008;105:14418–23.PubMedCrossRefPubMedCentral
26.
go back to reference Grajales-Reyes GE, Báez-Pagán CA, Zhu H, Grajales-Reyes JG, Delgado-Vélez M, García Beltrán WF, Luciano CA, Quesada O, Ramírez R, Gómez CM, Lasalde-Dominicci JA. Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin induced neuromuscular adverse drug reactions. Pharmacogenomics J. 2013;13(4):362–8.PubMedCrossRefPubMedCentral Grajales-Reyes GE, Báez-Pagán CA, Zhu H, Grajales-Reyes JG, Delgado-Vélez M, García Beltrán WF, Luciano CA, Quesada O, Ramírez R, Gómez CM, Lasalde-Dominicci JA. Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin induced neuromuscular adverse drug reactions. Pharmacogenomics J. 2013;13(4):362–8.PubMedCrossRefPubMedCentral
27.
go back to reference Borroni V, Baier CJ, Lang T, Bonini I, White MM, Garbus I, Barrantes FJ. Cholesterol depletion activates rapid internalization of submicronsized acetylcholine receptor domains at the cell membrane. Mol Membr Biol. 2007;24(1):1–15.PubMedCrossRef Borroni V, Baier CJ, Lang T, Bonini I, White MM, Garbus I, Barrantes FJ. Cholesterol depletion activates rapid internalization of submicronsized acetylcholine receptor domains at the cell membrane. Mol Membr Biol. 2007;24(1):1–15.PubMedCrossRef
28.
29.
go back to reference Turan A, Mendoza ML, Gupta S, You J, Gottlieb A, Chu W, Saager L, Sessler DI. Consequences of Succinylcholine Administration to Patients Using Statins. Anesthesiology. 2011;115(1):28–35.PubMedCrossRef Turan A, Mendoza ML, Gupta S, You J, Gottlieb A, Chu W, Saager L, Sessler DI. Consequences of Succinylcholine Administration to Patients Using Statins. Anesthesiology. 2011;115(1):28–35.PubMedCrossRef
Metadata
Title
Interaction between rosuvastatin and rocuronium in rat sciatic-gastrocnemius nerve-muscle preparation
Authors
Ashwin K. Panchasara
Jayshree C. Patel
Vishalkumar K. Vadgama
Manish J. Barvaliya
C. B. Tripathi
Publication date
01-10-2014
Publisher
Springer Japan
Published in
Journal of Anesthesia / Issue 5/2014
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-014-1792-z

Other articles of this Issue 5/2014

Journal of Anesthesia 5/2014 Go to the issue